Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma: The rationale for low-dose interleukin-2 therapy

Cancer Journal from Scientific American

Volumn 6, Issue SUPPL. 1, 2000, Pages

  Shah, Manisha H ^a   Baiocchi, Robert A ^a   Fehniger, Todd A ^a   Khatri, Vijay P ^b   Gould, Margaret ^b   Poiesz, Bernard ^c   Bernstein, Zale P ^b   Caligiuri, Michael A ^a,d  

^a OHIO STATE UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Cytokine therapy; HIV 1; Interleukin 2; Non Hodgkin's lymphoma; Translational research

Indexed keywords

CYTOKINE; INTERLEUKIN 2; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR; VIRUS RNA;

ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOMODULATION; MALIGNANT TRANSFORMATION; MOUSE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; DRUG SAFETY; FATIGUE; FEVER; ANIMAL; B CELL LYMPHOMA; BIOSYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOUSE MUTANT; REVIEW;

ANIMALS; HIV-1; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOMA, AIDS-RELATED; MICE; MICE, SCID;

EID: 0033848577     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jacobson L. Impact of highly effective anti-retroviral thetapy on the incidence of malignancies among HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:A39.
2. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
3. Chaisson RE, Gallant JE, Keruly JC et al. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998;12: 29-33.
4. Straus DJ, Huang J, Testa MA et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142 - low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998;16:3601-3606.
5. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994;15:575-581.
6. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-1176.
7. Murray RJ, Kurilla MG, Brooks JM et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992;176:157-168.
8. Baiocchi RA, Caligiuri MA Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Nad Acad Sci USA 1994;91:5577-5581.
9. Bernstein ZP, Porter MM, Gould M et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995; 86:3287-3294.
10. Bernstein Z et al. Phase I/II study of daily subcutaneous (SC) low dose interleukin-2 (IL-2) in AIDS-associated lymphomas (AIDS-NHL) [abstract]. Blood 1998;92:625a.
11. Caligiuri MA Murray C, Robertson MJ et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993;91: 123-132.
12. bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol 1997;27:354-360.
13. Bluman EM, Bartynski KJ, Avalos BR et al. Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines. J Clin Invest 1996;97: 2722-2727.
14. Fehniger TA, Herbein G, Yu H et al. Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol 1998;161:6433-6438.
15. Oliva A, Kinter AL, Vaccarezza M et al. Natural killer cells from human immunodeficiency vims (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 1998;102:223-231.
16. Trumpfheller C, Tenner-Racz K, Racz P et al. Expression of macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES genes in lymph nodes from HIV+ individuals: correlation with a Th1-type cytokine response. Clin Exp Immunol 1998; 112:92-99.
17. Jacobson EL, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996;93: 10405-10410.
18. Jouanguy E, Doffinger R, Dupuis S et al. IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Curr Opin Immunol 1999;11:346-351.
19. Carson WE, Ross ME, Baiocchi RA et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest 1995;96:2578-2582.
20. Chehimi J, Starr SE, Frank I et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994;179:1361-1366.
21. Gazzinelli RT, Bala S, Stevens R et al. HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit die synthesis of other parasite-induced monokines. J Immunol 1995;155:1565-1574.
22. Wu C, Warrier RR, Wang X et al. Regulation of interleukin-12 receptor beta1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells. Eur J Immunol 1997; 27:147-154.
23. Carson WE, Giri JG, Lindemann MJ et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180:1395-1403.
24. Khatri VP, Fehniger TA, Baiocchi RA et al. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J Clin Invest 1998;101:1373-1378.
25. Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Nad Acad Sci USA 1998;95:7556-7561.
26. Khatri VP, Baiocchi RA, Bernstein ZP et al. Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer. Cancer J Sci Am 1997;3[suppl 1]: S128-S136.